Literature DB >> 15467236

Synthesis and biological evaluation of quinuclidine derivatives incorporating phenothiazine moieties as squalene synthase inhibitors.

Tsukasa Ishihara1, Hirotoshi Kakuta, Hiroshi Moritani, Tohru Ugawa, Isao Yanagisawa.   

Abstract

Squalene synthase inhibitors have the potential to be superior hypocholesterolemic agents. A series of quinuclidine derivatives incorporating phenothiazine systems was synthesized in order to investigate the effects of their structure on the inhibition of hamster liver microsomal enzyme. (+/-)-3-(10-Methyl-10H-phenothiazin-3-ylmethoxy)quinuclidine hydrochloride (19) was the most potent inhibitor in this series with an IC(50) value of 0.12 microM. Oral dosing of compound 19 to hamsters demonstrated effective reduction of both plasma total cholesterol levels and plasma triglyceride levels. Compound 19 showed a reduced tendency to elevate plasma transaminase levels, an indicator of hepatotoxicity. Enantiomerically pure (-)-19, YM-53546, was found to be more potent than the corresponding (+)-enantiomer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467236     DOI: 10.1248/cpb.52.1204

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  3 in total

1.  Expression, purification, crystallization and X-ray analysis of 3-quinuclidinone reductase from Agrobacterium tumefaciens.

Authors:  Feng Hou; Takuya Miyakawa; Daijiro Takeshita; Michihiko Kataoka; Atsuko Uzura; Koji Nagata; Sakayu Shimizu; Masaru Tanokura
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-09-29

2.  Crystallization and preliminary X-ray analysis of the NADPH-dependent 3-quinuclidinone reductase from Rhodotorula rubra.

Authors:  Daijiro Takeshita; Michihiko Kataoka; Takuya Miyakawa; Ken-ichi Miyazono; Atsuko Uzura; Koji Nagata; Sakayu Shimizu; Masaru Tanokura
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-05-23

3.  Structural basis of stereospecific reduction by quinuclidinone reductase.

Authors:  Daijiro Takeshita; Michihiko Kataoka; Takuya Miyakawa; Ken-Ichi Miyazono; Shoko Kumashiro; Takahiro Nagai; Nobuyuki Urano; Atsuko Uzura; Koji Nagata; Sakayu Shimizu; Masaru Tanokura
Journal:  AMB Express       Date:  2014-02-07       Impact factor: 3.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.